Key Highlights

  • COMPASS Pathways (NASDAQ:CMPS) was up 12.37% to USD 9.45, a day after a 27.31% drop.
  • Cognition Therapeutics (NASDAQ:CGTX) was up 8.37% to USD 0.769 ahead of a November 5, 2026 call.
  • Rockwell Medical (NASDAQ:RMTI) was up 11.04% to USD 7.67 after a Vantive deal.
  • Bioventus (NASDAQ:BVS) was down 19.47% to USD 10.59 after third quarter results.
  • Emergent BioSolutions (NYSE:EBS) was down 18.63% to USD 5.24 after Revenue fell 52%.

COMPASS Pathways (NASDAQ:CMPS) (up USD 1.04, 12.37%): A Rebound Before Earnings

COMPASS Pathways (NASDAQ:CMPS) was up 12.37% to USD 9.45 in pre-market trading on November 3, 2026, from a November 2, 2026 close of USD 8.41. That close followed a 27.31% decline. Market reports said Usona Institute had submitted a Marketing application to the FDA for psilocybin in major depressive disorder. The company did not announce a reason, so the link rests on market commentary.

Third quarter results are scheduled for November 3, 2026, with a call at 8:00 a.m. ET. The company expects to complete its rolling FDA submission for COMP360 in the fourth quarter of 2026, and COMP360 has not been approved. It has no product revenue, and its cash balance had not been disclosed in the sources reviewed.

Cognition Therapeutics (NASDAQ:CGTX) (up USD 0.0594, 8.37%): Penny Stock Edges Up Ahead of November 5

Cognition Therapeutics (NASDAQ:CGTX) was up 8.37% to USD 0.769 in pre-market trading on November 3, 2026. The only company release identified was a November 2, 2026 notice of its third quarter call at 8:30 a.m. ET on November 5, 2026, which contains no new data.

Lead candidate zervimesine is investigational, and the FDA aligned on a pivotal Phase 3 trial in dementia with Lewy bodies, targeted to begin in mid-2027. Cash was about USD 34.8 million at June 30, 2026, expected to last into the fourth quarter of 2027. A Phase 3 program will likely need more capital, so dilution is a key risk for this penny stock.

Rockwell Medical (NASDAQ:RMTI) (up USD 0.7626, 11.04%): A Dialysis Deal Lifts Shares

Rockwell Medical (NASDAQ:RMTI) was up 11.04% to USD 7.67 in pre-market trading on November 3, 2026, after announcing a definitive agreement with Vantive. Rockwell will acquire Vantive's hemodialysis concentrates, monitors and water treatment systems, while the dialyzer portfolio is excluded. Closing is expected in mid-2027, subject to regulatory approvals.

The price and financing terms were not disclosed in the release content reviewed. Cash, equivalents and investments were USD 24.8 million at June 30, 2026, so funding is an open question, and any Equity issuance could dilute holders. Integration of an Italian plant adds execution risk.

Bioventus (NASDAQ:BVS) (down USD 2.56, 19.47%): Down Despite Higher Profit and Debt Paydown

Bioventus (NASDAQ:BVS) was down 19.47% to USD 10.59 in pre-market trading on November 3, 2026, after its third quarter report on November 2, 2026. Net sales were USD 142.4 million, up 2.7%, and adjusted EBITDA rose to USD 28.4 million. Net sales guidance was updated to USD 590 million to USD 595 million.

Growth was modest, with U.S. sales up only 1.0%. The company continues to review strategic alternatives, and no transaction was announced. Total debt, calculated from the balance sheet, was about USD 229.8 million, after a USD 15.0 million discretionary term Loan prepayment in the quarter.

Emergent BioSolutions (NYSE:EBS) (down USD 1.20, 18.63%): Revenue Drop and Lower Guidance

Emergent BioSolutions (NYSE:EBS) was down 18.63% to USD 5.24 in pre-market trading on November 3, 2026, after third quarter results released on November 2, 2026. Revenue was USD 110.0 million, down from USD 231.1 million, and the net loss was USD 32.7 million. Naloxone sales fell 42% to USD 43.5 million.

The company lowered 2026 revenue guidance to USD 600 million to USD 645 million from USD 645 million to USD 675 million, and its chief financial officer will retire effective December 31, 2026. The release did not disclose cash or total debt balances. Government order timing can make results uneven.

Where Things Stand

The five names show different reactions: a rebound at COMPASS Pathways, a pipeline-led penny stock at Cognition Therapeutics, deal-driven strength at Rockwell Medical, and sharp declines at Bioventus and Emergent BioSolutions after quarterly reports. Readers should watch the COMPASS results on November 3, 2026, the Cognition call on November 5, 2026, Rockwell's purchase price and financing, and the Bioventus strategic review. Pre-market Liquidity is thin, so opening trade may differ from early quotes.